Published online before print October 8, 2007, doi: 10.1161/CIRCULATIONAHA.107.704031
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;116:2029-2035.)
© 2007 American Heart Association, Inc.
Epidemiology |
Apolipoprotein A-II Is Inversely Associated With Risk of Future Coronary Artery Disease
From Departments of Vascular Medicine (R.S.B., G.M.D.-T., J.A.K., E.S.G.S., J.J.P.K.) and Cardiology (S.M.B.), Academic Medical Center, Amsterdam, the Netherlands; LipoScience Inc (J.D.O.), Raleigh, NC; Medical Research Council Epidemiology Unit (N.J.W.) Cambridge, United Kingdom; and Department of Public Health and Primary Care (R.L., K.-T.K.), Institute of Public Health, University of Cambridge, Cambridge, United Kingdom.
Correspondence to John J.P. Kastelein, MD, PhD, Academic Medical Center, Department of Vascular Medicine, Room F4-159.2, PO Box 22660, 1100 DD, Amsterdam, the Netherlands. E-mail j.j.kastelein{at}amc.uva.nl
Received April 4, 2007; accepted August 31, 2007.
Background— Although the vasculoprotective effects of apolipoprotein A-I (apoA-I), the major protein associated with high-density lipoprotein, have been universally accepted, apoA-II has been suggested to have poor antiatherogenic or even proatherogenic properties. To study this suggestion more closely, we evaluated how serum levels of apoA-II and apoA-I relate to the risk of future coronary artery disease (CAD) in a large, prospective study.
Methods and Results— We performed a nested case-control study in the prospective EPIC-Norfolk (European Prospective Investigation into Cancer and Nutrition–Norfolk) cohort. Case subjects (n=912) were apparently healthy men and women aged 45 to 79 years who developed fatal or nonfatal CAD during a mean follow-up of 6 years. Control subjects (n=1635) were matched by age, gender, and enrollment time. Conditional logistic regression was used to quantify the relationship between serum apoA-II levels and risk of CAD. Serum apoA-II concentration was significantly lower in case subjects (34.5±6.3 mg/dL) than in control subjects (35.2±5.8 mg/dL) and was inversely associated with risk of CAD, such that patients in the upper quartile (>38.1 mg/dL) had an odds ratio of 0.59 (95% confidence interval 0.46 to 0.76) versus those in the lowest quartile (<31.1 mg/dL; P for linearity <0.0001). After adjustment for fasting time, alcohol use, and cardiovascular risk factors (systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, body mass index, smoking, diabetes mellitus, and C-reactive protein), the corresponding risk estimate was 0.48 (95% confidence interval 0.34 to 0.67, P for linearity <0.0001). Surprisingly, additional adjustment for serum apoA-I levels did not affect risk prediction of apoA-II for future CAD (odds ratio 0.49, 95% confidence interval 0.34 to 0.68, P for linearity <0.0001). Also, after adjustment for high-density lipoprotein particle number and size, apoA-II was still associated with the risk of future CAD (odds ratio 0.62, 95% confidence interval 0.43 to 0.90, P for linearity 0.02).
Conclusions— ApoA-II is associated with a decreased risk of future CAD in apparently healthy people. These findings imply that apoA-II itself exerts effects on specific antiatherogenic pathways. On the basis of these findings, discussion of the potential proatherogenic effects of apoA-II can cease.
CLINICAL PERSPECTIVE
Related Article:
-
Issue Highlights
Circulation 2007 116: 1997.[Full Text]
This article has been cited by other articles:
 |
|
 |
|
  R. Movva and D. J. Rader Laboratory Assessment of HDL Heterogeneity and Function Clin. Chem., May 1, 2008; 54(5): 788 - 800. [Abstract] [Full Text] [PDF]
|
|